The present invention provides: a novel human-derived monoclonal antibody that binds specifically to the F protein of the human metapneumovirus and that neutralizes the human metapneumovirus; an antigen-binding fragment of said antibody; and a pharmaceutical composition that includes said antibody or said antigen-binding fragment thereof.